Galantamine Effects on Cognitive Function in Marijuana Users
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
To evaluate galantamine's effects on cognitive performance in marijuana users. Galantamine,
an acetylcholine esterase inhibitor, is approved for treatment of Alzheimer's disease.
Current marijuana users show impaired cognitive functioning, which predicts poor treatment
response to behavioral treatments in this population. Whether cognitive impairment in
marijuana users will improve with medication treatment has not been evaluated. We hypothesize
that galantamine, compared to placebo, will improve cognitive performance in marijuana
users.Galantamine, compared to placebo, will improve working memory, verbal learning/memory
and response inhibition functions in marijuana users.
Phase:
Phase 1
Details
Lead Sponsor:
Yale University
Collaborators:
National Institute on Drug Abuse (NIDA) US Department of Veterans Affairs VA Office of Research and Development